The molecular scenario of breast cancer has become more complex in the last few years. Distinguishing between BRCAassociated, sporadic, HER2-enriched and triple-negative tumors is not sufficient to allow effective clinical management. Basal-like breast cancer, a subtype of triple-negative breast cancer, differs from others grouped under this heading. Commonalities between BRCA-related tumors and basal-like breast cancers (BRCAness phenotype) are highly relevant to ongoing clinical trials, in particular those investigating targeted therapies (e.g. PARP inhibitors) in sporadic breast tumors. The 'gold standard' to identify basal-like phenotype is DNA microarray, but integrated results could provide a panel of biomarkers helpful in identifying 'BRCAness' tumors (e.g. copy number aberrations, abnormal protein localization and altered transcriptional levels) and other molecular targets, such as APE1,the inhibition of which is emerging as an attractive breast cancer treatment in certain therapeutic settings.
introduction
Breast cancer is a complex and heterogeneous pattern of diseases up to now classified by histopathological features and immunostaining for hormone receptor (ER, PgR) and HER2. The majority of breast tumors are ER/PgR-positive with HER2 normally expressed and have good prognosis [1, 2] . ER-positive patients account for ∼65% of breast tumors in women <50 years old [2] ; PgR-positive cases account for 60% of breast tumors [3] , while 6% of breast tumors are hormone receptor-positive and HER2-positive. Notwithstanding their ER-positivity, these have a poor prognosis due to their resistance to hormonal treatment [4] . Tumors lacking ER, PgR and HER2 are classified as triplenegative breast cancers (TNBCs) and comprise about 15% of breast cancers [5] . TNBCs have a poor prognosis in terms of disease-free survival and overall survival [6, 7] ; these patients are sensitive to chemotherapy but quickly relapse and develop visceral metastasis.
Histopathological features are not sufficient to capture the heterogeneity of breast diseases, thus molecular classification aims to resolve this heterogeneity by genome-wide approaches. Molecular profiling through DNA microarray allows us to distinguish six subtypes: luminal A, luminal B, HER2-enriched tumors, basal-like tumors, normal-like and claudin-low [8] [9] [10] which differ in incidence [11] , response to therapies [1] and survival [12] . The luminal A and luminal B subtypes are characterized by positivity of ER, PgR and ER-responsive genes. Luminal A subtype overexpresses ERα, GATA3, B-cell CLL/ lymphoma 2, cytokeratin (CK) 8, CK18, ERBB3, ERBB4; luminal B tumors express lower levels of luminal A-specific genes [9, 13] . ER-negative tumors comprise HER2-enriched and normal-like breast cancers. Molecular classification of these subgroups is the subject of studies and not yet completely clarified. Claudin-low tumors were identified by Herschkowitz et al. [10] , who analyzed 13 samples. They showed low expression of tight junction proteins (claudin 3, 4 and 7) and E-cadherin and enrichment of immune-response gene clusters, such as CD4 and CD79a genes, typically expressed by T-and B-lymphoid cells [12] . Basal-like breast cancer (BLBC) is a distinct group characterized by overexpression of basal markers (e.g. cytokeratins 5 and 8) and enrichment of genes involved in proliferation, DNA damage response and cell cycle checkpoint. Importantly, it often shares ER, PgR and HER2 negativity with TNBCs, composed of basal-like and claudin-low tumors, and partially overlaps with these (Table 1) .
A major challenge is to find markers that clearly identify BLBCs. Considering the tumor characteristics of patients carrying mutations in the susceptibility gene BRCA1, many studies have underlined the fact that BLBCs share many features with BRCA1-mutated tumors [14] . Moreover, it has been observed that three quarters of BRCA1-associated tumors are BLBCs [15] . Dysfunctions of the BRCA1 pathway detected in BLBCs mainly regard the impairment of double-strand break (DSB) repair through homologous recombination (HR), leading to genomic instability. The identification of such a deficiency in BLBCs has important clinical relevance because DSBimpairment is the basis for specific target treatments. Thus, DSB repair pathway deficiency identifies a specific immunophenotype, called 'BRCAness' because of its similarities with BRCA-related tumors, with not yet been clearly identified genetic basis. Identification of markers of the BRCAness phenotype is mandatory for both a more precise classification of breast cancer and a selective recruitment of patients to specific therapy.
In this review, we focus on basal-like tumors and DNA repair pathway functionality, pointing to a subset of patients with the BRCAness phenotype that could benefit from therapy targeting DNA repair deficits, based or not on synthetic lethality.
TNBCs are not BLBCs
In the last few years, researchers have demonstrated that TNBCs and BLBCs are not synonymous and that they only partially overlap. Kreike et al. [16] analyzed the gene expression profile of 97 TNBC samples. The hierarchical cluster analysis showed that all TNBCs clustered similarly to BLBCs, and they concluded that histopathological characterization is sufficient to detect a basal-like phenotype because of their co-clustering. However, genome-wide approaches revolutionized and enriched the landscape of TNBCs leading to a more complex scenario: the overlap between TNBCs and BLBCs varies between 60% and 90% [17] . The former are histotypically characterized whereas the latter are defined through gene expression profiling. Lehmann et al. [18] analyzed gene expression profiles from 21 breast cancer datasets and selected 587 TNBCs sets divided into training and validation datasets. Gene ontology and differential gene expression profile analyses led to the identification of seven TNBC subgroups: a basal-like 1 enriched for proliferation genes (e.g. AURKA, AURKB, CENPA, CENPF, CCNA2 BIRC5) and DNA damage response genes (e.g. CHEK1, FANCA, RAD51, RAD21); a basal-like 2 displaying enrichment in EGF, MET, Wnt/β-catenin and IGF1R pathways; an immunomodulatory group characterized by elevated expression of immune response (e.g. cytokine, IL-12 and IL-7 pathways); amesenchymal and mesenchymal stem-like set that showed specific gene ontologies enriched in cell motility and cell differentiation pathways (e.g. TGF-β pathway); and luminal (androgen receptor) set featuring hormonally regulated pathway such as steroid synthesis, porphyrin metabolism and androgen/estrogen metabolism.
Heterogeneity of TNBCs was further confirmed by Bertucci et al. [19] , who analyzed a cohort of TNBCs (123 basal-like and 49 nonbasal-like tumors) and a second series of BLBCs (160 triple-negative and 37 nontriple-negative patients). The results confirmed the heterogeneity of TNBCs, (both basal and nonbasal-like) at histochemical and molecular levels compared with BLBCs, supporting the need to improve TNBC classification.
BRCAness: the hallmark of basal-like tumors BRCA1 and DNA damage repair Many types of DNA damage could be acquired during lifetime:
• Distortion of the DNA double helix repaired through the nucleotide excision repair (NER) pathway (xeroderma pigmentosum-related genes (XPA, XPC etc.) and Cockayne's syndrome-related genes (ERCC6 etc.)
• Nonhelix-distorting nucleotide base lesions or single-strand breaks through the base excision repair (BER) pathway (AP endonuclease, DNA glycosylases)
• Incorrectly paired nucleotides, insertion and deletion loops repaired through mismatch repair (MMR) (MSH2, MLH1)
• Single-strand breaks and DSBs repaired through homologous recombination, HR (BRCA1/2, BRT1, BLM)
• Chromosomal breaks through the nonhomologous end joining (NHEJ) pathway (ku70, ku80, DNA-PKcs, XRCC4).
BRCA1 pathway proteins play a key role in the DNA damage response, not only as actors in HR but also in other DNA repair pathways, cell cycle checkpoints (G2/M and spindle assembly) and in chromatin remodelling [20, 21] . Natural radiation, such as ultraviolet radiation, could lead to DNA breaks, but also occur after chromosome exchange genetic material (e.g. 'crossing over' during meiosis). The role of BRCA1 in DSBs repair has been clearly defined. In normal cells, BRCA1 and BRCA2 proteins interact with RAD51 during the repair of DNA DSBs [22] . These three proteins play a key role in maintaining genome stability and their interaction is often impaired in BRCA-related tumors. BRCA1 could be involved not only in HR but also in other DNA repair pathways, e.g. promoting NHEJ in DNA DSBs repair [23] or NER [24] . The role of BRCA1 in promoting higher fidelity DNA repair by NHEJ could be explained by its high affinity for branched DNA structures. As regards foci formation due to DSBs, BRCA1 is involved in the regulation of the complex MRE-RAD50-NBS1 (MRN) in the initial steps of their formation [25] . Moreover, BRCA1 co-localize with γ-H2AX in DSB repair foci, indicating a role in recruiting repair factors [26, 27] . Moreover, it is part of BRCA1-associated genome surveillance complex (BASC) which influences the choice of repair pathway depending upon the type of DNA lesion [28] .
The role of BRCA1 in BER is emerging. Cells carrying BRCA1 mutations are deficient in the transcription-coupled repair of oxidative damage [29, 30] repaired through BER. In breast cancer, genomic instability can be induced by errors in the repair of the abasic sites generated by natural estrogens. Estrogen metabolism is altered in breast cancer leading to an abnormal increase in the levels of catechol quinones, especially the estrogen-3,4-quinones which react with DNA and form almost exclusively depurinating adducts. These adducts spontaneously dissociate from DNA to form abasic sites and generate mutations which will be corrected by prone-error BER [31] .
Saha et al. [32] studied the correlation between BRCA1 expression and enzymes involved in the BER pathway in MCF-7 and T47D cell lines (human mammary adenocarcinoma cell lines). BRCA1 overexpression caused a 2-fold increase in the mRNA levels of DNA glycosylases OGG1 and NTHL1, of REF1/APE1, which is involved in processing of abasic sites and of the scaffold protein XRCC1.
BLBCs and BRCA1-associated tumors: what do they have in common?
BLBCs are characterized by the expression of genes found in basal/myoepithelial cells of the normal breast [8, 33] . Clinically, they are high-grade and highly proliferative tumors with poor prognosis. Gene expression profiling is considered the 'gold standard' to characterize BLBCs but it is not yet applied in clinical practice. Immunohistochemical (IHC) identification could be the simplest way to detect BLBC patients but there is no consensus. The 'IHC signature' of Nielsen et al. [34] has been widely used as a surrogate of gene expression evaluation through microarrays. This signature includes lack of expression of ER and HER2 and overexpression of cytokeratin 5/6 (CK 5/6) and/or epidermal growth factor receptor (EGFR). The immunophenotype of BLBCs is also characterized by positive expression of p53, P-cadherin, caveolins 1 and 2, cyclin E, c-Kit, fascin, moesin, vimentin, laminin, cyclin D1, p27 and MUC1 [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] .
However, to date, only genomic profiling is able to detect most features specific to BLBCs: a high degree of genomic instability, dysfunctions of the BRCA1 pathway and TP53 mutation [46] and inactivation of the Rb pathway [47] . BRCA1 mutations in sporadic BLBCs are rare [48] but BRCA1-deficiency highlights this immunophenotype and alterations relating to BRCA1 loss of function have been observed. In BLBCs, the loss of 17q21, where BRCA1 maps [49] , and low expression of BRCA1 at transcriptional and protein levels has been reported. Moreover, in 11%-13% of BLBCs, BRCA1-promoter hypermethylation was observed [50, 51] and a high expression of ID4, a transcriptional repressor of BRCA1, has been measured [52] . Copy number alterations (CNAs) associated with BLBCs including many aberrations are also found in BRCA1 mutation carriers. CNAs observed in BLBCs include the loss of 10p containing MAP3K8, ZEB1 and FAM107B [53, 54] and the deletion of 16q [55] and of 4q, which contains INPP4B, a tumor suppressor involved in PI3K signaling [56] frequently deleted in TNBCs/BLBCs. BRCA1-related tumors and BLBCs exhibit frequent loss of 5q11-35 [57] , where important genes involved in DNA repair, such as RAD17, RAD50 and RAP80map. In fact, Weigman et al. [58] observed that in ∼80% of tumors with 5q11-35 (RAD17 + RAD50) loss, there was also RB1/13q14.2 deletion and in ∼60% 5q11-35 and TP53/17p13.1 loss co-occurs. These data led authors to speculate that the loss of the RAD17 + RAD50 locus with deletions of other regions contributes to impaired HR and then to genomic instability.
The BRCAness phenotype is correlated with alterations in DNA repair pathways. Sporadic BLBCs and BRCA1-associated tumors share the loss of the PTEN locus, which point to a deficit in the HR pathway [59, 60] . The presence of TP53 mutations in BRCA1-associated tumors is due to deficiency in DNA repair mechanisms induced by BRCA1 loss of function [40, 58] . TP53 mutational status has been analyzed by Holstege et al. [61] , who observed that TP53 mutations occur in almost all BRCA1-related tumors and BLBCs, compared with in 20%-50% of luminal tumors. In detail, 52.4% of BRCA1-mutated patients and 57.1% of BLBCs were carriers of complex truncating mutations compared with 7% of luminal cases. The high frequency of TP53 mutations in sporadic BLBCs may relate to a dysfunction of DSB repair pathway. In fact, an impaired HR mechanism leads to selective pressure against TP53 wild-type cells in order to abrogate the p53 cell cycle checkpoint [62] and, eventually, proliferating cells with deficient DSB repair accumulate genetic aberrations. Interestingly, proliferating premenopausal breast epithelial cells lack the expression of hormone receptors [63] , see also Barcellos-Hoff and Kleinberg. As BRCA1-related tumors occur with high frequency in premenopausal glands [64] , one can speculate that HR deficiency and related genomic instability lead to tumor development in hormone receptor-negative premenopausal breast epithelia [61] .
Sabatier et al. [65] described a non-BRCA1/2 BLBC with a somatic homozygous loss of BARD1, which maps at 2q34-35. BARD1 protein is a binding partner of BRCA1 [66] which interacts with TP53, RAD51, H2AFX [67] [68] [69] . The tumor exhibited a BRCA1-mutated-like molecular profile, even if other mechanisms of BRCA1 inactivation were not detected (BRCA1- [70] observed that depletion of BARD1 and downregulation of BRCA1 are embryonically lethal in mice. For this reason, Sabatier et al. [65] speculated that loss of the BARD1 locus could be another inactivation mechanism of BRCA1.
However, many cases of BLBC have normal expression and localization of BRCA1 [71] but abnormal expression of other proteins involved in DNA repair, CHEK1, RAD51, RAD50, ATM [18, 71, 72] indicating the complexity of a BRCAness phenotype.
Not only DSBs repair pathways require BRCA1 full functionality, but also BER. Alli et al. [72] reported defective repair of oxidative damage through BER in basal-like cell lines. One of the most common oxidative damages is the introduction of 8-oxoguanine due to GC > TA transversion. Alli et al. [72] analyzed BER efficiency in a panel of BRCA1-mutated (SUM149PT, SUM1315MO2, HCC1937, MDA-MB436) and basal-like (BT529, hs578T, MDA-MB468) cell lines. Interestingly, they noted that cell lines were found to be defective in oxidative damage repair and that knockdown of OGG1 (8-oxoguanine DNA glycosylase) results in increased sensitivity to PARP inhibition [72] . PARP1 is a player in BER and its targeting efficacy is due to deficiency in HR, observed primarily in BRCA1/2-related tumors.
In recent years, the involvement of miRNAs in tumorigenesis has been intensely studied. Moskwa et al. [73] studied the role of miR182 in a panel of breast cancer cell lines, both BRCA1-proficient and -deficient. They demonstrated that BRCA1 is targeted by miR182 in basal-like ER-negative cell lines, and also found a decrease of miR182 level after IR exposure. PARPinhibitor effectiveness was demonstrated by injecting either MDA-MB231 cells (low endogenous miR182 and high BRCA1 protein) stably expressing miR182 or scramble control into nude mice. After 10 days of treatment, miR182 overexpressing tumors showed a delayed tumor growth, underling a role of miR182 in PARP sensitivity [73] .
Genetic, genomic and epigenetic changes indicate that BLBCs and BRCA1-associated tumors could share common clinical management strategies. For this reason, it is urgent that BRCAness phenotypes be clearly identified through the use of biomarkers in clinical practice.
molecular markers for BRCAness
BRCAness markers need to be detected and validated for use in clinical practice. To date, the basal-like phenotype is detected through gene expression profiling. However, several studies have shown that many molecular markers could be useful in identifying patients to be recruited in clinical trials of PARP inhibitors (PARPi) including patients with sporadic breast cancers. A panel of markers for clinical practice would be useful potentially for stratification of patients with BLBCs included in trials.
Copy number aberrations, as we have already reported, may reflect impairment of DSB repair and genomic instability. In particular, the loss of the RAD17 + RAD50 locus has been demonstrated to indicate loss of BRCA1 function. TP53 mutational status could also be integrated in clinical practice. In fact, Holstege et al. [61] showed that 90% of BRCA1-mutated tumors and 95% of BLBCs carried more TP53 mutations than the luminal subtype, and also that they complex truncating mutations may be featured.
RAD51 functionality evaluation as a marker of HR impairment has also been correlated in different studies to BLBCs [18] . PARP1 expression has been analyzed due to its importance in target therapy with PARP1. PARP1 mRNA expression has been measured in a cohort of breast cancer samples by Ossovkaya et al. [74] , who found a significant upregulation in TNBCs compared with receptor-positive samples. Futhermore, Domagala et al. [75] analyzed nuclear and cytoplasmic expression of PARP1 in a cohort of BRCA1-related TNBCs and BLBCs. They found that 96.9% of BRCA1-nonrelated BLBCs and 81% of BRCA1-related BLBCs had higher nuclear PARP1 expression. Only 7% of BRCA1-associated breast cancers do not exhibit nuclear expression of PARP1. This evidence supports a role for the expression of PARP1 to be evaluated not only in BLBCs but also in patients carrying mutations: PARPi may only be applicable to some BRCA mutation carriers.
APE1, an enzyme involved in BER whose function could be potentially targeted alternatively to PARP1, is a new field of research in breast tumors. Recently, acetylation on lysine 35 of APE1 was analyzed in a cohort of TNBCs [76] . Acetylation of APE1 has been correlated with modulation of its DNA repair activity [77] and Poletto et al. [76] found deregulation of acetylation of APE1, opening up a possible new way of classifying breast carcinomas.
APE1 is the enzyme responsible for apurinic/apyrimdinic (AP) sites that are intermediate in the BER pathway. Measurement of AP site accumulation could be useful not only to identify patients treatable with APE1i but also to verify their efficacy. Aldehyde reactive probe (ARP) assay for quantitative detection of AP sites may be carried out in peripheral blood mononuclear cells or in tumor tissue samples as speculated by Sultana et al. [78] .
Finally, MGMT (O 6 -methylguanine-methyltransferase) is an enzyme involved in a single-step mechanism of repair which is responsible of repairing alkylating adducts of guanine. MGMT silencing through promoter hypermethylation has been demonstrated to sensitize cells to alkylating agents in different types of tumor, such as glioblastoma [79, 80] and melanoma [81] . IHC studies in breast cancer have shown that low expression of MGMT is associated with negative hormone receptor status and poor prognosis [82] . Low levels of MGMT mRNA in breast cancer have already been demonstrated [83] and, recently, Fumagalli et al. [84] analyzed methylation status of MGMT in a cohort of TNBCx, both BRCA1 and non-BRCA1-associated cancer. They found that one third of BRCArelated TNBCs and 63.6% of wild-type TNBCs had aberrant MGMT methylation. Although MGMT function is BRCA1 independent, the simultaneous impairment of DSB repair pathways, and hypermethylation of MGMT may identify patients who could potentially benefit from novel chemotherapeutic combinations (e.g. cisplatin and temozolomide). [85] . PARP inhibition in BRCA1/2-associated breast cancer is based on the concept of 'synthetic lethality'. Such a concept was developed for the first in time in Drosophila [86] , and Hartwell et al. [87] applied it to cancer. Its basis is the loss of function of a gene while a viable may predispose to lethality with the loss of a second interrelated gene. In patients carrying mutations in BRCA1/2, the HR pathway is not functional and inhibition of BER leads to DSB accumulations and stalled replication forks that are repaired [88] . Tutt et al. [89] demonstrated the effectiveness of the PARP inhibitor in women with advanced BRCA1/2-associated breast cancer treated with PARPi AZD-2281 (olaparib). Recently, Chuang et al. evaluated the efficacy of AG-014699 (rucaparib), AZD-2281, ABT-888 (veliparib) and BSI-201 (iniparib) in TNBC cell lines. The results showed differences in PARP inhibitor efficacy, because according to Lehmann et al. [18] , treated cell lines were classified as basal-like 1 (MDA-MB468), mesenchymal-like (MDA-MB231) and mesenchymal (Cal-51) subgroups. These preclinical results confirm the need to correctly define TNBC subtypes in order to more optimally define those respond to PARPi.
Several clinical trials (www.clinicaltrials.gov) to evaluate PARPi treatment in TNBCs are ongoing (Table 2) . O'Shaughnessy [90] published results of a randomized phase II trial comparing the effects of chemotherapy (carboplatin and gemcitabine) alone and iniparib in combination with chemotherapy in TNBCs. The median overall survival (OS) increased up to 12.3 months in the iniparib group and median progression-free survival (PFS) increased to 5.9 months in patients treated with iniparib plus chemotherapy, BRCA1/2 status was not evaluated. The phase III trial [91] recruiting 519 patients comparing the same regimens and presented at the American Society of Clinical Oncology (ASCO) 2011, while displaying some increasing PFS in the arm treated with iniparib did not achieve the required statistical significance [90] . This failure may be in part specifically related to iniparib's lack of PARPi. However, for evaluating PARP inhibition in TNBC, questions remain on better identifying BRCAness phenotype in order to enhance.
APE1 inhibitors: work in progress
The large number of members of the PARP family may contribute to toxic effects of nonspecific activity PARPi in clinical trials [92, 93] . For this reason, detection of other molecular targets in BER and, in particular, APE1 is emerging. APE1 is responsible in the processing of apurinic/apyrimdinic (AP) sites, and obligatory intermediates forming after DNA damage or hydrolysis catalyzed are N-glycosylic bond, thus acting not only as AP endonuclease but also as 3 0 -5 0 exonuclease, 3 0 -phosphatase and 3 0 -phosphodiesterase. These enzymatic activities take place in a unique active site at Cterminal position of the protein [94] . Several studies have demonstrated that APE1 (apurinic/apyrimdinic endonuclease) inhibition sensitizes cells to alkylating agents, such as temozolomide [95] [96] [97] [98] . In breast cancers inhibition of APE1 endonuclease activity by lucanthone enhanced cytotoxicity of temozolomide [99] . In gliomas, high expression of APE1 was correlated with resistance to radiotherapy [100] . Sultana et al. [78] evaluated a new synthetic lethal approach in a panel of cell lines (V-C8: BRCA2-deficient; V-E5: ATM-like deficient); MDA-MB436: BRCA1-deficient; MDA-MB31) treated with three different APE1. They compared results treating cells with NU1025, a PARPi and E330, an inhibitor of the redox activity of APE1. MDA-MB-436, a cell line classified as mesenchymal-like [18] , was sensitive to APE1i [78] . These data suggest that evaluation of repair mechanisms, as well as inhibition of APE1 should be introduced into clinical research to resolve some shortcomings of PARP inhibitor effects. As the only enzyme involved in the obligatory step of processing AP sites, studies to detect small-molecule inhibitors of APE1 are ongoing and reviewed by Al-Safi et al. [101] their clinical application is in its infancy.
conclusion
In the last few years, many research groups have been focusing on subtypes of breast tumors. It would appear that BRCA1/2 mutational status and hormone receptor evaluation are clearly not sufficient to stratify such patients. At present, a panel of biomarkers could be useful in identifying DSB-deficient BLBCs or with the so-called BRCAness phenotype. Preclinical studies regarding other molecular targets, such as APE1i, are a promising field of research to improve the synthetic lethality approach introduced by PARPi. These studies are yet needed to be integrated into study of BLBCs. Biomarker validation requires multicenter studies in order to study a greater cohort of patients. This effort has to be parallel to ongoing clinical trials in order to obtain clearly interpretable results. The phase III clinical trial of iniparib in TNBCs may be an example that additional studies are needed in this area of clinical research. Therefore, although breast cancer treatment has become an increasingly complex scenario, integrated analyses including detection of molecular targets and biomarker validation, is the way forward to 'fix the puzzle'. 
